Beam Therapeutics Has Initiated A Search For A New CFO After Terry-Ann Burrell Shared Plans To Depart On August 9 To Join JPMorgan Chase

Beam Therapeutics +1.82%
JPMorgan Chase & Co. -0.26%

Beam Therapeutics

BEAM

24.66

+1.82%

JPMorgan Chase & Co.

JPM

294.60

-0.26%

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that its chief financial officer, Terry-Ann Burrell, will be leaving the company effective August 9, 2024 to pursue a new opportunity as vice chairman of investment banking at JPMorgan Chase. As part of a transition process, the company has initiated a search for a successor.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.